Jason M. Pogue
Biochemistry, Genetics and Molecular Biology · University of Michigan
Publications
263
Citations
10,457
Est. group size
~5
Recurring co-author estimate
Active years
20
Publishing since 2007
Typically publishes in teams of ~5 · 24% small-team papers (≤3 authors) · across 25 venues
- What's Behind DOOR Number 2? Recent Applications From Post-Hoc Analyses of Infectious Diseases Randomized Clinical Trials
Open Forum Infectious Diseases · 2026
- Gram-negative bacterial infection randomized controlled trials (RCTs) in the 21st century: characteristics and evolution
JAC-Antimicrobial Resistance · 2026
- Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?
Antimicrobial Agents and Chemotherapy · 2025
- Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i>
Open Forum Infectious Diseases · 2025
- P-1258. Unlocking Potentials: The Impact of Meropenem, Meropenem-vaborbactam, and Ceftazidime-avibactam in Combatting Carbapenem-Resistant <i>Enterobacter cloacae</i> in Epithelial Lining Fluid and Serum
Open Forum Infectious Diseases · 2025
- The Antibiotic Pipeline Has Delivered for Drug-Resistant Gram-Negative Pathogens, Now Global Access Must Follow
Clinical Infectious Diseases · 2025
- IMMU-70. Novel multispecific CAR T cell therapy to address GBM antigen heterogeneity and immunosuppression
Neuro-Oncology · 2025
- Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant <i>Enterobacter cloacae</i>
Antimicrobial Agents and Chemotherapy · 2025
- Evaluation of Aminoglycoside Dosing Regimens Adjusted for Renal Function and In Vitro Susceptibility Test Interpretive Criteria for Enterobacterales and <i>Pseudomonas aeruginosa</i> : Brief Summary
Open Forum Infectious Diseases · 2025
- Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia or Pneumonia
Clinical Infectious Diseases · 2024
- Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?
Current Infectious Disease Reports · 2024
- Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing
Clinical Infectious Diseases · 2024
- Is it time to join the oral antibiotics bandwagon?
The Lancet Infectious Diseases · 2024
- Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches
Antimicrobial Agents and Chemotherapy · 2023
- Nut Cracked? Does the ACORN Trial End the Debate Surrounding Vancomycin and Piperacillin-Tazobactam Combination Therapy and Increased Risk for Acute Kidney Injury?
Open Forum Infectious Diseases · 2023
- Open Forum Infectious Diseases×71
- Clinical Infectious Diseases×22
- Antimicrobial Agents and Chemotherapy×16
- Infectious Diseases and Therapy×8
- Clinical Microbiology and Infection×6
- Samuel L Aitken
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Paul Lephart
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Karen Bush
Biochemistry, Genetics and Molecular Biology · Indiana University
- Keith S. Kaye
Biochemistry, Genetics and Molecular Biology · University of Michigan
- Walaiporn Wangchinda
Biochemistry, Genetics and Molecular Biology · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile